AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Neuroendocrine Tumors.

PF-07826390 is under development for the treatment of solid tumors including non-small cell lung cancer, colorectal cancer and renal cell carcinoma. It acts by targeting leukocyte immunoglobulin like ...

Nearly 200 nations at the Cop28 climate summit in Dubai agreed to the deal, which calls on them to "transition away" from ... who had called for the term "phase out" of fossil fuels to be used ...

Deconfined quantum criticality represents a novel class of phase transitions that fall outside ... material candidates show a weakly-first order transition. Here the authors introduce a Nordic ...